Vault-13

Venrock Adviser, LLC

NEW YORK, NY · CIK 1615982 · 13F filing filed 2024-05-15

SEC-registered investment adviser since 2014 · limited liability company

As an employer

Where they work

people there (dot area)number not reportedmain officeHover or tap a dot. Australian and UK companies are placed at their business or registered address, with their staff across the whole country.

Offices

From Form ADV: the main office and the other offices where it does advisory work (at most the 25 largest), with the people doing investment work at each. “About” is worked out: the firm's investment staff less its other offices. Each city links to the other managers there.

CityCountryPeople
New York, NY (main office)United States United Statesabout 11
Palo Alto, CAUnited States United States

Map: places from GeoNames (CC BY 4.0), outlines from Natural Earth.

$2.1bn reported value +44.2% vs Q4 2023
38positions
63.6%in top 10
9 new 14 added 6 reduced 7 sold out vs Q4 2023

Holdings, Q1 2024

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 APOGEE THERAPEUTICS INC COM COM 8,493,321 $564.4m26.85% 26.85% UnchangedShares held: Q2 2023 0, Q3 2023 8.5m, Q4 2023 8.5m, Q1 2024 8.5m
2 4D MOLECULAR THERAPEUTICS IN COM FDMT FDMT 4,400,000 $140.2m6.67% 6.67% AddedShares held: Q2 2023 3.0m, Q3 2023 3.0m, Q4 2023 3.4m, Q1 2024 4.4m +976.0k +975,969 28.5%
3 OCULAR THERAPEUTIX INC COM OCUL OCUL 12,762,462 $116.1m5.52% 5.52% AddedShares held: Q2 2023 0, Q3 2023 0, Q4 2023 7.8m, Q1 2024 12.8m +5.0m +4,986,702 64.1%
4 SPYRE THERAPEUTICS INC COM NEW SYRE SYRE 2,171,782 $82.4m3.92% 3.92% ReducedShares held: Q2 2023 0, Q3 2023 0, Q4 2023 2.4m, Q1 2024 2.2m -200.9k -200,932 -8.5%
5 MERUS N V COM MRUS MRUS 1,790,214 $80.6m3.83% 3.83% ReducedShares held: Q2 2023 1.7m, Q3 2023 1.7m, Q4 2023 2.1m, Q1 2024 1.8m -358.0k -358,000 -16.7%
6 PHARVARIS N V COM PHVS PHVS 3,395,606 $78.5m3.73% 3.73% UnchangedShares held: Q2 2023 1.3m, Q3 2023 1.6m, Q4 2023 3.4m, Q1 2024 3.4m
7 KALVISTA PHARMACEUTICALS INC COM KALV KALV 6,249,731 $74.1m3.53% 3.53% AddedShares held: Q2 2023 2.9m, Q3 2023 2.9m, Q4 2023 4.1m, Q1 2024 6.2m +2.2m +2,157,000 52.7%
8 ENLIVEN THERAPEUTICS INC COM ELVN ELVN 4,026,331 $70.8m3.37% 3.37% AddedShares held: Q2 2023 2.2m, Q3 2023 3.0m, Q4 2023 3.0m, Q1 2024 4.0m +1.1m +1,071,429 36.3%
9 VIRIDIAN THERAPEUTICS INC COM VRDN VRDN 3,882,671 $68.0m3.23% 3.23% AddedShares held: Q2 2023 3.1m, Q3 2023 3.1m, Q4 2023 3.9m, Q1 2024 3.9m +48 +48 0.0%
10 DIANTHUS THERAPEUTICS INC COM DNTH DNTH 2,094,373 $62.8m2.99% 2.99% AddedShares held: Q2 2023 0, Q3 2023 927.7k, Q4 2023 927.7k, Q1 2024 2.1m +1.2m +1,166,667 125.8%
11 DYNE THERAPEUTICS INC COM DYN DYN 2,173,913 $61.7m2.94% 2.94% UnchangedShares held: Q2 2023 2.2m, Q3 2023 2.2m, Q4 2023 2.2m, Q1 2024 2.2m
12 APPLIED THERAPEUTICS INC COM APLT APLT 9,075,000 $61.7m2.94% 2.94% AddedShares held: Q2 2023 5.7m, Q3 2023 5.7m, Q4 2023 6.2m, Q1 2024 9.1m +2.8m +2,825,000 45.2%
13 ORIC PHARMACEUTICALS INC COM ORIC ORIC 4,394,527 $60.4m2.87% 2.87% AddedShares held: Q2 2023 2.1m, Q3 2023 2.1m, Q4 2023 2.4m, Q1 2024 4.4m +2.0m +1,966,142 81.0%
14 ASTRIA THERAPEUTICS INC COM CATB CATB 3,608,645 $50.8m2.42% 2.42% AddedShares held: Q2 2023 0, Q3 2023 0, Q4 2023 3.2m, Q1 2024 3.6m +382.8k +382,839 11.9%
15 MERSANA THERAPEUTICS INC COM COM 11,328,000 $50.7m2.41% 2.41% UnchangedShares held: Q2 2023 0, Q3 2023 11.3m, Q4 2023 11.3m, Q1 2024 11.3m
16 ENGENE HOLDINGS INC COM COM 2,565,841 $43.5m2.07% 2.07% NewShares held: Q2 2023 0, Q3 2023 0, Q4 2023 0, Q1 2024 2.6m
17 PRAXIS PRECISION MEDICINES I COM NEW PRAX PRAX 706,126 $43.1m2.05% 2.05% AddedShares held: Q2 2023 0, Q3 2023 0, Q4 2023 353.6k, Q1 2024 706.1k +352.5k +352,500 99.7%
18 HILLEVAX INC COM COM 2,075,000 $34.5m1.64% 1.64% UnchangedShares held: Q2 2023 0, Q3 2023 2.0m, Q4 2023 2.1m, Q1 2024 2.1m
19 COGENT BIOSCIENCES INC COM COGT COGT 5,129,167 $34.5m1.64% 1.64% AddedShares held: Q2 2023 4.7m, Q3 2023 4.7m, Q4 2023 4.7m, Q1 2024 5.1m +445.0k +445,000 9.5%
20 EDGEWISE THERAPEUTICS INC COM EWTX EWTX 1,818,182 $33.2m1.58% 1.58% NewShares held: Q2 2023 0, Q3 2023 0, Q4 2023 0, Q1 2024 1.8m
21 CABALETTA BIO INC COM CABA CABA 1,563,952 $26.7m1.27% 1.27% ReducedShares held: Q2 2023 2.0m, Q3 2023 2.0m, Q4 2023 2.6m, Q1 2024 1.6m -1.0m -1,000,000 -39.0%
22 ARVINAS INC COM ARVN ARVN 627,788 $25.9m1.23% 1.23% UnchangedShares held: Q2 2023 0, Q3 2023 0, Q4 2023 627.8k, Q1 2024 627.8k
23 TAYSHA GENE THERAPIES INC COM SHS TSHA TSHA 9,000,000 $25.8m1.23% 1.23% ReducedShares held: Q2 2023 0, Q3 2023 14.4m, Q4 2023 10.4m, Q1 2024 9.0m -1.4m -1,412,872 -13.6%
24 AQUESTIVE THERAPEUTICS INC COM AQST AQST 5,555,555 $23.7m1.13% 1.13% NewShares held: Q2 2023 0, Q3 2023 0, Q4 2023 0, Q1 2024 5.6m
25 TERNS PHARMACEUTICALS INC COM COM 3,410,058 $22.4m1.06% 1.06% ReducedShares held: Q2 2023 3.0m, Q3 2023 3.1m, Q4 2023 4.5m, Q1 2024 3.4m -1.1m -1,087,059 -24.2%
26 ADVERUM BIOTECHNOLOGIES INC COM NEW ADVM ADVM 1,556,419 $22.0m1.05% 1.05% NewShares held: Q2 2023 0, Q3 2023 0, Q4 2023 0, Q1 2024 1.6m
27 CELCUITY INC COM CELC CELC 970,000 $21.0m1.00% 1.00% ReducedShares held: Q2 2023 2.1m, Q3 2023 2.1m, Q4 2023 1.9m, Q1 2024 970.0k -915.5k -915,538 -48.6%
28 ABIVAX SA SPONSORED ADS ABVX ABVX 1,345,780 $19.2m0.92% 0.92% AddedShares held: Q2 2023 0, Q3 2023 0, Q4 2023 998.6k, Q1 2024 1.3m +347.2k +347,210 34.8%
29 IMMATICS N.V SHS IMTX IMTX 1,750,000 $18.4m0.87% 0.87% NewShares held: Q2 2023 0, Q3 2023 0, Q4 2023 0, Q1 2024 1.8m
30 LYRA THERAPEUTICS INC COM LYRA LYRA 2,576,093 $16.0m0.76% 0.76% AddedShares held: Q2 2023 924.2k, Q3 2023 924.2k, Q4 2023 2.6m, Q1 2024 2.6m +500 +500 0.0%
31 CG ONCOLOGY INC COM CGON CGON 350,000 $15.4m0.73% 0.73% NewShares held: Q2 2023 0, Q3 2023 0, Q4 2023 0, Q1 2024 350.0k
32 CENTURY THERAPEUTICS INC COM IPSC IPSC 3,405,133 $14.2m0.68% 0.68% NewShares held: Q2 2023 0, Q3 2023 0, Q4 2023 0, Q1 2024 3.4m
33 TREVI THERAPEUTICS INC COM TRVI TRVI 3,422,675 $11.8m0.56% 0.56% AddedShares held: Q2 2023 3.4m, Q3 2023 3.4m, Q4 2023 3.4m, Q1 2024 3.4m +278 +278 0.0%
34 TENAYA THERAPEUTICS INC COM TNYA TNYA 1,555,556 $8.1m0.39% 0.39% NewShares held: Q2 2023 0, Q3 2023 0, Q4 2023 0, Q1 2024 1.6m
35 MINERALYS THERAPEUTICS INC COM MLYS MLYS 555,554 $7.2m0.34% 0.34% NewShares held: Q2 2023 0, Q3 2023 0, Q4 2023 0, Q1 2024 555.6k
36 ACELYRIN INC COM COM 937,113 $6.3m0.30% 0.30% UnchangedShares held: Q2 2023 0, Q3 2023 864.3k, Q4 2023 937.1k, Q1 2024 937.1k
37 EYEPOINT PHARMACEUTICALS INC COM NEW EYPT EYPT 250,000 $5.2m0.25% 0.25% UnchangedShares held: Q2 2023 0, Q3 2023 0, Q4 2023 250.0k, Q1 2024 250.0k
38 OLEMA PHARMACEUTICALS INC COM OLMA OLMA 77,042 $872.1k0.04% 0.04% UnchangedShares held: Q2 2023 0, Q3 2023 77.0k, Q4 2023 77.0k, Q1 2024 77.0k

Sold out since Q4 2023

SecurityTickerShares held beforeValue then
RAYZEBIO INC 4,030,471 $250.6m4.0m shares
AMBRX BIOPHARMA INC 2,070,000 $29.5m2.1m shares
RHYTHM PHARMACEUTICALS INC RYTM RYTM 495,983 $22.8m496.0k shares
SAVARA INC SVRA SVRA 3,500,000 $16.4m3.5m shares
GH RESEARCH PLC GHRS GHRS 1,318,327 $7.6m1.3m shares
ADVERUM BIOTECHNOLOGIES INC 5,147,547 $3.9m5.1m shares
MILESTONE PHARMACEUTICALS IN MIST MIST 925,048 $1.5m925.0k shares